Previous 10 | Next 10 |
Small-cap CNS Pharmaceuticals (CNSP) drops 12% after pricing of an underwritten public offering of 5M shares and warrants to purchase up to 2.5M shares of common stock, at combined price of $2/share & warrant.Five-year warrants will have an exercise price of $2.20/share.Underwri...
CNS Pharmaceuticals Announces Pricing of $10.0 Million Public Offering PR Newswire HOUSTON , Dec. 23, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of ...
Cellectar Biosciences CLRB -22% after it intends to offer and sell shares of its common stock in a public offering.Kubient KBNT -13% after prices equity offering at $5.10.Big Rock Partners Acquisition (BRPA) -13%.Voyager Therapeutics VYGR -11% afte...
Gainers: Ocugen (OCGN) +114%.Big Rock Partners Acquisition (BRPA) +110%.Aurora Mobile (JG) +50%.Aqua Metals (AQMS) +45%.NantHealth (NH) +39%.Sportsman's Warehouse Holdings (SPWH) +37%.Aemetis (AMTX) +30%.Foresight Autonomous Holdings (FRSX) +29%.QuantumScape (QS) +28%.Cyclacel Pharmaceut...
Gainers: Ocugen (OCGN) +90%, NantHealth (NH) +35%, Organovo (ONVO) +25%, Genprex (GNPX) +23%, Spero Therapeutics (SPRO) +14%.Losers: Soligenix (SNGX) -54%, SOS (SOS) -39%, Venus Concept (VERO) -23%, BioCryst Pharmaceuticals...
Gainers: EyeGate Pharmaceuticals (EYEG) +78%, Editas Medicine (EDIT) +42%, NantKwest (NK) +30%, Liminal BioSciences (LMNL) +29%, Agios Pharmaceuticals (AGIO) +24%.Losers: Scopus BioPharma (SCPS) -17%, uniQure (QURE) -16%, C...
Gainers: Mereo BioPharma (MREO) +91%, Cyclo Therapeutics (CYTH) +44%, Petros Pharmaceuticals (PTPI) +29%, CNS Pharmaceuticals (CNSP) +17%, Humanigen (HGEN) +17%.Losers: Mesoblast (MESO) -34%, Virios Therapeutics (VIRI) -30%, BioCardia (BCDA) -...
CNS Pharmaceuticals (CNSP) +62%.Cyclo Therapeutics (CYTH) +47%.Mereo BioPharma Group (MREO) +38% on licensing pact with Ultragenyx.DermTech (DMTK) +23% after announcing topline results from its TRUST Study of the company’s non-invasive melanoma rule-out test, the Pigmented Le...
CNS Pharmaceuticals (CNSP) will host a conference call and live webcast today at 8:30 am ET to discuss its Investigational New Drug ((IND)) approval for Berubicin, for the treatment of Glioblastoma Multiforme ((GBM)), and planned Phase 2 Berubicin clinical trial. By the end of the Q1 2021, CN...
CNS Pharmaceuticals Announces Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin HOUSTON , Dec. 17, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the developme...
News, Short Squeeze, Breakout and More Instantly...
CNS Pharmaceuticals Inc. Company Name:
CNSP Stock Symbol:
NASDAQ Market:
CNS Pharmaceuticals Inc. Website:
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in next month’s 2024 SNO/ASCO CNS Cancer Conference. The event will be held...
HOUSTON, TX / ACCESSWIRE / July 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its ab...
New research suggests that cancer may have been plaguing individuals even thousands of years ago. Researchers at the University of Cambridge’s Duckworth Laboratory Collection studied skulls obtained from Ancient Egypt, observing lesions which they believe may have been left by malignant t...